Assessment of the immune response to tumors is growing in importance as the prognostic
implications of this response are increasingly recognized, and as immunotherapies are …

Breast cancer is a heterogeneous disease in terms of histology, therapeutic response,
dissemination patterns to distant sites, and patient outcomes. Global gene expression …

CD8 T cell is an essential component of tumor-infiltrating lymphocytes (TIL) and tumor
immune microenvironment (TIME). Using the xCell CD8 T cell score of whole tumor gene …

Immune checkpoint blockade (ICB) has improved outcomes for patients with advanced
cancer, but the determinants of response remain poorly understood. Here we report …

Background Retrospective studies provide conflicting interpretations of the effect of inherited
genetic factors on the prognosis of patients with breast cancer. The primary aim of this study …

Background Genome-wide association studies (GWAS) have identified 94 common single-
nucleotide polymorphisms (SNPs) associated with breast cancer (BC) risk and 18 …

Background: Previously, small studies have found that BRCA1 and BRCA2 breast tumors
differ in their pathology. Analysis of larger datasets of mutation carriers should allow further …

Immune checkpoint inhibitors have emerged as a potent new class of anticancer therapy.
They have changed the treatment landscape for a range of tumors, particularly those with a …

Background: The contribution of BRCA germline mutational status to breast cancer patients'
prognosis is unclear. We aimed to systematically review and perform meta-analysis of the …

Breast cancer patients with the same stage of disease can have markedly different treatment
responses and overall outcome. The strongest predictors for metastases (for example, lymph …